|
Good Evening,
I know its a little late but I had a free moment tonight from dealing with
kids and did a bottom bounce chart scan and came across MITD.
At first glance MITD didn't look like anything out of the ordinary, a nice
chart set up with increasing volume.
Did a small scan on the boards and noticed a large amount of chatter going
on regarding their recent 10q and Pr's.
- Announced a new revenue stream with up to 52pct growth
- MITD is the sub investigator in a Phase 3 clinical trial for Melinta Therapeutics
- Announced net profit of aporx $21K and the end of Q2 2014
- Reduced operating expenses by 71pct while increasing Income from operations.
Not bad for a 10 cent play.
In the mean time, volume is rising, chatter is on the up and up and the
chart is bullish:
 RSI - At breakout point, level 51
Price - Trending up, tested two resistance levels today.
MACD - About to do a bullish cross over with its signal line.
Acc/Dist - On the rise, shows demand and accumulation.
Its not often you stumble across a great chart with solid fundamentals.
If you are still up, start your research on MITD and make sure its on
top of you watch list for tomorrow, as its chart indicators might be on
to a bullish uptrend.
Sincerely,
SSR
Tickerlogix has received two thousand dlrs via a bank wire for the awareness of MITD from a third party Stockchat LLC
Disclaimer – By reading our newsletter, website, twitter, Facebook and chat you agree to the terms of our disclaimer, which are subject to change at any time. TickerLogix, its owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using TickerLogix service you agree not to hold TickerLogix, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website may be based on EOD or intraday data. TickerLogix may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.
|
